Funded Biotechnology Startups in Princeton
Princeton's biotechnology sector shows 13 recorded funding rounds spanning September 2021 through August 2025, with deal stages ranging from Pre-Seed and S…
Princeton's biotechnology sector shows 13 recorded funding rounds spanning September 2021 through August 2025, with deal stages ranging from Pre-Seed and Seed through Post-IPO Debt and Private Equity. The largest disclosed raise in the set is IVERIC bio's $250M Post-IPO Debt round, closed in July 2022 — more than 27x the next largest disclosed amount ($9M, Soligenix, May 2023).
Four companies — Sonnet BioTherapeutics, Agile Therapeutics, KayoThera, and Advaxis — each reported exactly $5M, making it the most common disclosed figure despite spanning different stage types. Seven of the 13 rounds carry a "Series Unknown" classification, while three — 4M Therapeutics, RICOVR Healthcare, and CitiusTech — do not disclose a dollar amount. The most recent entry is 4M Therapeutics (Seed, August 2025), and three additional rounds closed in 2024: Sonnet BioTherapeutics ($5M, November), RICOVR Healthcare (undisclosed, October), and Agile Therapeutics ($5M, February).
Most recent rounds
13 shownRelated listings
Frequently asked
What is the largest disclosed round among Princeton biotech companies in this dataset?
IVERIC bio closed a $250M Post-IPO Debt round in July 2022, the only nine-figure transaction in the set. Soligenix ($9M, May 2023) and NJ Bio ($6M, March 2023) are the next two largest disclosed raises.
Which funding stage appears most frequently in this group?
"Series Unknown" is the most common classification, applied to seven of the 13 rounds — including Sonnet BioTherapeutics, Agile Therapeutics, Soligenix, NJ Bio, and RICOVR Healthcare. Named stages in the set include Seed, Pre-Seed, Series A, Private Equity, Post-IPO Debt, Post-IPO Equity, and Grant.
How much Princeton biotech funding activity has occurred in 2024 and 2025?
Four rounds fall within that window. In 2025, 4M Therapeutics closed an undisclosed Seed round in August. In 2024, Agile Therapeutics raised $5M in February, RICOVR Healthcare closed an undisclosed round in October, and Sonnet BioTherapeutics raised $5M in November.
Are there post-IPO companies still raising capital in this dataset?
Two companies fit that profile. IVERIC bio raised $250M in Post-IPO Debt in July 2022, and Advaxis closed a $5M Post-IPO Equity round in February 2022, both representing publicly listed companies accessing capital within the covered period.
Which rounds have undisclosed amounts, and does that skew the picture?
Three rounds — 4M Therapeutics (Seed, August 2025), RICOVR Healthcare (Series Unknown, October 2024), and CitiusTech (Private Equity, October 2022) — list no dollar figure. Since all three span different years and stages, the gap affects breadth more than it distorts any single time period.
What is the smallest disclosed raise in this dataset?
Origin raised $50K in October 2023, the smallest disclosed dollar amount in the set. Certara's $100K Grant (September 2021) and Lactiga's $1M Pre-Seed (September 2022) are the next two smallest.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.